Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

Taher Modarressi can be contacted at [email protected].

Taher Modarressi reports having served on scientific advisory boards for Novartis, Novo Nordisk, NewAmsterdam Pharma, and Regeneron and speaker's bureaus for Amgen, Eli Lilly, Abbott, AstraZeneca, and Madrigal Pharmaceuticals. No other potential conflict of interest relevant to this letter was reported.